Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatolog... 12/04/2023 Healthcare Access to innovation Almirall recently announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England... Partners - Almirall
ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b ada... 03/04/2023 Healthcare Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial Partners - Oryzon Genomics
Canadian Intelectual Property Office (CIPO) has conceded ZIP Solutions “Split Inteins and ... 24/03/2023 Healthcare Access to innovation In vitro diagnostics Drug discovery Rare diseases Innovative drugs Personalized medicine Advanced therapies Gene editing International The tool has many biotech applications Partners - Biotechnology Assets
Pharma Partnering Summit 2023 Munich Germany Del 25/05/2023 08:00 to 26/05/2023 19:00 Healthcare Access to innovation International
Jornada; Regulación europea IVDR para tecnologías de diagnóstico In vitro CNIO, Melchor Fernández Almagro 3, 28029 Madrid y On-Line España Del 27/04/2023 09:00 to 27/04/2023 13:00 Healthcare Access to innovation In vitro diagnostics
Peaches Biotech, Universidad Autónoma of Madrid and its Foundation create the first Univer... 16/03/2023 Healthcare Innovative drugs Personalized medicine Advanced therapies The UAM-Peaches Chair will promote research and teaching in the areas of Cellular Therapy and Regenerative Medicine One... Partners - PEACHES BIOTECH S.L.
ORYZON announces First Patient In in FRIDA, a Phase Ib trial with iadademstat in relapsed/... 15/03/2023 Healthcare Access to innovation Primary objectives: to assess safety, tolerability and RP2D Partners - Oryzon Genomics
Jornada de innovación abierta con la farmacéutica japonesa FUSO Virtual Japón Del 24/04/2023 to 28/04/2023 Healthcare Access to innovation International
Jornada de innovación abierta con la farmacéutica japonesa DyDo Virtual Japón Del 29/05/2023 to 02/06/2023 Healthcare Access to innovation International
ORYZON announces clinical candidate nomination of ORY-4001 for the treatment of CNS disord... 13/03/2023 Healthcare Access to innovation Corporate Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model Partners - Oryzon Genomics
